Drug Trial Radar · NCT07076290
A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
Last checked: Nov 20, 2026Latest source record: Jan 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Apr 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Rise Therapeutics LLCIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 82 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- COPD Exacerbation
- COPD Exacerbation Acute
Interventions
R-3750Drug
R-3750 DP; Lactococcus lactis expressing Surface Layer Protein A (SlpA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the treatment-related adverse events of R-3750Time frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.